Turner Syndrome Market Research Report - Forecast till 2027

Turner Syndrome Market research report, diagnosis (physical examination, prenatal testing, karyotyping), treatment (progesterone replacement therapy, psychological therapy), end users (hospitals & clinics, academic institutes) - Forecast till 2027

ID: MRFR/Pharma/3723-HCR | | Region: Global | 110 pages

Turner Syndrome Market Scenario


Turner Syndrome is a rare chromosomal condition diagnosed in the female population. It occurs when one of the X chromosome is partially or completely missing. Women with condition are shorter than the average female and are unable to conceive due to early loss of the ovarian function. Webbed neck, a low hairline at the neck’s back, lymphedema are some of the common symptoms of the disease. Increasing prevalence of the disease and rising female population are the major factors that drives the turner syndrome market during the forecast period. According to the National Library of Medicine in 2017, about 1 in 2,500 new-born girls, worldwide, were affected with the Turner Syndrome, making it one of the causes of female-fetal-miscarriages and stillbirths. Moreover, according to the World Bank the female population increased from 3.60 billion in 2014 to 3.68 billion in 2016. Additionally, the increasing FDA approvals for the treatment of the diseases followed by growing biotechnology sector and increasing awareness of the women health is expected to fuel the turner syndrome market growth. However, high annual treatment cost followed by its related side effects like vomiting, carpal tunnel syndrome, insulin resistance/ high blood sugar, worsening of scoliosis, and others is one of the major restrains for the turner syndrome market growth. This along with low per capita healthcare expenditure and lack of the awareness within the low and middle income countries is projected to restrain the turner syndrome market growth during the forecast period.


The turner syndrome market is estimated to grow at an approximate CAGR of 13.0% from 2017 to 2023.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


 Figure 1:- Turner Syndrome Market share, by Region
Turner Syndrome Market


Sources: WHO, annual reports, press release, white paper, and company presentation


Segmentation


The turner syndrome market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of the diagnosis, the turner syndrome market is categorised into physical examination, prenatal testing, karyotyping and others. The prenatal testing segment, by diagnosis, is sub-segmented into ultrasound test, amniocentesis, chorionic villus sampling, and others.


On the basis of the treatment, the turner syndrome market is segmented into human growth hormone therapy, oestrogen replacement therapy, progesterone replacement therapy, psychological therapy, and others.


On the basis of the end user, the turner syndrome market is segmented into hospitals & clinics, academic institutes, research organization, and others.


Regional Analysis


America dominates the turner syndrome market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure, increasing female population followed by the presence of developed economies and healthcare sector within the region fuels the market growth.


Europe is the second largest market, in the turner syndrome market. Rising research and development in healthcare sector, huge patient population, growing biotechnology sector are the major drivers for the market growth within the region. According to the International Trade Administration, the total turnover for the biotechnology sector in Germany reached from USD 3,280 million in 2015 to USD 3,410 million in 2016. It was also estimated that in 2016, the R&D expenditure for biotech sector was about USD 1,040 million


Asia Pacific region is the fastest growing market. Increasing awareness for women health, rising healthcare expenditures and growing healthcare sector are the major drivers for the market growth within the region during the forecast period. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.


The Middle East & Africa has the least share in the turner syndrome market.  The presence of poor economies and stringent government policies, especially in the African region restrains the market growth within the region. Majority of the market in the Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the developed economies like Saudi Arabia, Kuwait, and Qatar within the region. 


Research Methodology
Turner Syndrome Market 2018


Sources: WHO, annual reports, press release, white paper, and company presentation


Key players for turner syndrome market


Cooper Pharma (India), Pfizer Inc. (U.S.), Lilly USA, LLC (U.S.), Genentech, Inc. (U.S.), Novo Nordisk (Denmark), Smiths Medical (U.S.), Rocket Medical plc. (U.K), Medtronic (U.S.), Sanofi (France), and others are some of the key players in the turner syndrome market.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   13.0% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2023
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cooper Pharma (India), Pfizer Inc. (U.S.), Lilly USA, LLC (U.S.), Genentech, Inc. (U.S.), Novo Nordisk (Denmark), Smiths Medical (U.S.), Rocket Medical plc. (U.K), Medtronic (U.S.), Sanofi (France), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Growing biotechnology sector
  • Increasing awareness of the women health


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Turner Syndrome market is expected to expand at 13% CAGR from 2017 to 2023.

    Rising prevalence of the condition and the increasing female populace are primary drivers of the global Turner syndrome market.

    Lack of awareness of the disease and the paucity of medical reimbursement schemes are factors expected to impede the global Turner Syndrome market growth.

    The Americas is expected to dominate in the global Turner Syndrome market till 2023 due to developed economies in the region and the noticeably large female population.

    Genentech, Inc., Sanofi, Lilly USA, LLC, Novo Nordisk, Smiths Medical, Pfizer Inc., Medtronic, Rocket Medical plc., and Cooper Pharma are prominent players of the global Turner Syndrome market.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Turner Syndrome Market, by Diagnosis

    6.1 Introduction

    6.2 Physical Examination

    Market Estimates & Forecast, 2020 – 2027

    6.3 Prenatal Testing

    Market Estimates & Forecast, 2020 – 2027

    6.3.1 Ultrasound Test

    6.3.2 Amniocentesis

    6.3.3 Chorionic Villus Sampling

    6.3.4 Others

    6.4 Karyotyping

    Market Estimates & Forecast, 2020 – 2027

    6.5 Others

    Chapter 7. Global Turner Syndrome Market, by Treatment

    7.1 Introduction

    7.2 Human Growth Hormone Therapy

    Market Estimates & Forecast, 2020 – 2027

    7.3 Oestrogen Replacement Therapy

    Market Estimates & Forecast, 2020 – 2027

    7.4 Progesterone Replacement Therapy

    Market Estimates & Forecast, 2020 – 2027

    7.5 Psychological Therapy

    Market Estimates & Forecast, 2020 – 2027

    7.6 Others

    Chapter 8. Global Turner Syndrome Market, by End User

    8.1 Introduction

    8.2 Hospitals & Clinics

    Market Estimates & Forecast, 2020 – 2027

    8.3 Academic Institutes

    Market Estimates & Forecast, 2020 – 2027

    8.4 Research Organizations

    Market Estimates & Forecast, 2020 – 2027

    8.5 Others

    Chapter 9. Global Turner Syndrome Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 U.S.

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 U.K

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Cooper Pharma

    11.1.1 Company Overview

    11.1.2 Diagnosis Overview

    11.1.3 Financials

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Pfizer Inc.

    11.2.1 Company Overview

    11.2.2 Diagnosis Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Lilly USA, LLC

    11.3.1 Company Overview

    11.3.2 Diagnosis Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Genentech, Inc.

    11.4.1 Company Overview

    11.4.2 Diagnosis/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Novo Nordisk

    11.5.1 Company Overview

    11.5.2 Diagnosis Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Smiths Medical

    11.6.1 Company Overview

    11.6.2 Diagnosis Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Rocket Medical plc.

    11.7.1 Overview

    11.7.2 Diagnosis Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Medtronic

    11.8.1 Overview

    11.8.2 Diagnosis Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Sanofi

    11.9.1 Overview

    11.9.2 Diagnosis Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.0 Others

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Global Turner Syndrome Market

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Global Turner Syndrome Industry Synopsis, 2020 – 2027

    Table 2 Global Turner Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Global Turner Syndrome Market by Region, 2020 – 2027, (USD Million)

    Table 4 Global Turner Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 5 Global Turner Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 6 Global Turner Syndrome Market by End Users, 2020 – 2027, (USD Million)

    Table 7 North America Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 8 North America Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 9 North America Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 10 US Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 11 US Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 12 US Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 13 Canada Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 14 Canada Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 15 Canada Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 16 South America Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 17 South America Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 18 South America Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 19 Europe Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 20 Europe Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 21 Europe Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 22 Western Europe Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 23 Western Europe Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 24 Western Europe Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 25 Eastern Europe Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 26 Eastern Europe Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 27 Eastern Europe Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 28 Asia Pacific Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 29 Asia Pacific Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 30 Asia Pacific Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    Table 31 Middle East & Africa Turner Syndrome Marketby Diagnosis, 2020 – 2027, (USD Million)

    Table 32 Middle East & Africa Turner Syndrome Marketby Treatment, 2020 – 2027, (USD Million)

    Table 33 Middle East & Africa Turner Syndrome Marketby End Users, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Turner Syndrome Market

    Figure 3 Segmentation Market Dynamics for Global Turner Syndrome Market

    Figure 4 Global Turner Syndrome Market Share, by Diagnosis 2020

    Figure 5 Global Turner Syndrome Market Share, by Treatment, 2020

    Figure 6 Global Turner Syndrome Market Share, by End Users, 2020

    Figure 7 Global Turner Syndrome Market Share, by Region, 2020

    Figure 8 North America Turner Syndrome Market Share, by Country, 2020

    Figure 9 Europe Turner Syndrome Market Share, by Country, 2020

    Figure 10 Asia Pacific Turner Syndrome Market Share, by Country, 2020

    Figure 11 Middle East & Africa Turner Syndrome Market Share, by Country, 2020

    Figure 12 Global Turner Syndrome Market: Company Share Analysis, 2020 (%)

    Figure 13 Cooper Pharma: Key Financials

    Figure 14 Cooper Pharma: Segmental Revenue

    Figure 15 Cooper Pharma: Geographical Revenue

    Figure 16 Pfizer Inc.: Key Financials

    Figure 17 Pfizer Inc.: Segmental Revenue

    Figure 18 Pfizer Inc.: Geographical Revenue

    Figure 19 Lilly USA, LLC: Key Financials

    Figure 20 Lilly USA, LLC: Segmental Revenue

    Figure 21 Lilly USA, LLC: Geographical Revenue

    Figure 22 Genentech, Inc.: Key Financials

    Figure 23 Genentech, Inc.: Segmental Revenue

    Figure 24 Genentech, Inc.: Geographical Revenue

    Figure 25 Novo Nordisk: Key Financials

    Figure 26 Novo Nordisk: Segmental Revenue

    Figure 27 Novo Nordisk: Geographical Revenue

    Figure 28 Smiths Medical: Key Financials

    Figure 29 Smiths Medical: Segmental Revenue

    Figure 30 Smiths Medical: Geographical Revenue

    Figure 31 Rocket Medical plc.: Key Financials

    Figure 32 Rocket Medical plc.: Segmental Revenue

    Figure 33 Rocket Medical plc.: Geographical Revenue

    Figure 34 Medtronic: Key Financials

    Figure 35 Medtronic: Segmental Revenue

    Figure 36 Medtronic: Geographical Revenue

    Figure 37 Sanofi: Key Financials

    Figure 38 Sanofi: Segmental Revenue

    Figure 39 Sanofi: Geographical Revenue